Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2011 | Research

Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells

Authors: Xiaohong Zhao, Li Yang, Jianguo Hu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Abstract

Aims

Here we aimed to firstly investigate the role of miR-27a in proliferation and multidrug resistance of gastric cancer cells.

Methods

The role of miR-27a in gastric cancer cells was detected using MTT assay, soft agar assay, flow cytometry assay, nude mice assay, real-time PCR, western blot and reporter gene assay, etc.

Results

Down-regulation of miR-27a could inhibit porliferation of gastric cancer cells in vitro and in vivo. Down-regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase accumulation and decrease releasing amount of adriamycin in gastric cancer cells. Down-regulation of miR-27a could significantly decrease the expression of P-glycoprotein and the transcriptional activity of cyclin D1, and up-regulate the expression of p21.

Conclusions

MiR-27a might play important roles in porliferation and drug resistance of gastric cancer. MiR-27a might be considered as a useful target for cancer therapy.

Available only for authorised users

Bhardwaj A, Singh S, Singh AP: MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2010, 2 (5): 213-219.PubMedCentralPubMed

Kurokawa R: Long noncoding RNA as a regulator for transcription. Prog Mol Subcell Biol. 2011, 51: 29-41.CrossRefPubMed

Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, Zheng X: Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010, 55 (9): 2545-51.CrossRefPubMed

Nishi H, Ono K, Horie T, Nagao K, Kinoshita M, Kuwabara Y, Watanabe S, Kimura T: MicroRNA-27a regulates beta cardiac myosin heavy chain gene expression by targeting thyroid hormone receptor {beta}1 in neonatal rat ventricular myocytes. Mol Cell Biol. 2011, 31 (4): 744-55.PubMedCentralCrossRefPubMed

Ma Y, Yu S, Zhao W, Lu Z, Chen J: miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010, 298 (2): 150-8.CrossRefPubMed

Allen DL, Loh AS: Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. Am J Physiol Cell Physiol. 2011, 300 (1): 124-37. 10.1152/ajpcell.00142.2010.CrossRef

Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B: Hsa-mir-27ª genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci. 2010, 101 (10): 2241-7.CrossRefPubMed

Li ZM, Hu S, Xiao L, Wang J, Cai J, Yu LL, Wang ZH: Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells. Zhonghua Fu Chan Ke Za Zhi. 2010, 45 (5): 372-5.PubMed

Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010, 119 (1): 125-30.CrossRefPubMed

10.

Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, Safe S: MicroRNA-27a indirectly regulates estrogen receptor {alpha} expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology. 2010, 151 (6): 2462-73.PubMedCentralCrossRefPubMed

11.

Kim SY, Kim AY, Lee HW, Son YH, Lee YS, Kim JB: miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun. 2010, 392 (3): 323-8.CrossRefPubMed

Title: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells
Authors: Xiaohong Zhao
Li Yang
Jianguo Hu
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-30-55

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Efficacy of Mesenchymal Stem Cells in Suppression of Hepatocarcinorigenesis in Rats: Possible Role of Wnt Signaling

Salivary α-amylase exhibits antiproliferative effects in primary cell cultures of rat mammary epithelial cells and human breast cancer cells

Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro

A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

Antisense oligodeoxynucleotides targeting ATM strengthen apoptosis of laryngeal squamous cell carcinoma grown in nude mice

Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer